Search | IOVS | ARVO Journals

Showing 1 – 20 of 25

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Predictability of the 12-week dosing status at Week 48 for patients receiving brolucizumab in HAWK and HARRIER

Pravin U Dugel; Gabriele Elisabeth Lang; Sam Razavi; Andreas Weichselberger; Yuichiro Ogura; David M Brown

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1455. doi:

ARVO Annual Meeting Abstract July 2018

Comparative assessment of anatomical outcomes for nAMD patients treated with brolucizumab and aflibercept: 16-week data from the HAWK and HARRIER studies

Rishi P Singh; Andreas Weichselberger; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1464. doi:

ARVO Annual Meeting Abstract July 2018

Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER

Glenn J Jaffe; Adrian H C Koh; Yuichiro Ogura; Andreas Weichselberger; Frank G. Holz; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1624. doi:

ARVO Annual Meeting Abstract July 2018

Quantitative assessment of changes in retinal vascular density and morphology among patients with diabetic retinopathy using spectral domain optical coherence tomography angiography (SD-OCTA)

Kaitlin Kogachi; TAI-CHI LIN; Neal V Palejwala; Sujit Itty; Jeremy D. Wolfe; Kimberly A Drenser; Antonio Jr. Capone; Pravin U Dugel; Xuejuan Jiang; Anoush Shahidzadeh; Zhongdi Chu; Ruikang K Wang; Amir H Kashani

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):739. doi:

ARVO Annual Meeting Abstract June 2017

Quantitative spectral-domain optical coherence tomography angiography (OCTA) of Diabetic Retinopathy (DR) Severity

TAI-CHI LIN; Priyanka Gogte; Neal Palejwala; Anoush Shahidzadeh; Sujit Itty; Mark S Humayun; Andrew A Moshfeghi; Hossein Ameri; Zhongdi Chu; Ruikang K Wang; Jeremy D Wolfe; Pravin U Dugel; Amir H Kashani

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1653. doi:

ARVO Annual Meeting Abstract June 2017

Persistent diabetic macular edema after 6 months of anti-VEGF therapy is associated with diminished long-term improvement in vision: a post-hoc analysis of Protocol I

Scott M Whitcup; Joanna Campbell; Anat Loewenstein; Pravin U Dugel; Nancy Holekamp; Szilard Kiss; Albert J Augustin; Vanessa Shih; Jeff Lai; Charles Clifton Wykoff; Srinivas R Sadda

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1906. doi:

ARVO Annual Meeting Abstract June 2017

3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration

Rafael Varona; Annaig Le-Halpere; Peter A Campochiaro; Jeffrey Heier; Pravin U Dugel; Mark Barsamian; Annie Purvis; Mario Cabrera-Salazar; Cheryl Delacono; Najwa Mostafa; Abraham Scaria; Ronald BUGGAGE

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2321. doi:

ARVO Annual Meeting Abstract June 2017

Assessing the safety and efficacy of dexamethasone intraocular implant for macular edema after cataract surgery in patients with diabetes.

Neal Palejwala; Sravanthi Vegunta; Pravin U Dugel; Derek Kunimoto; karim jamal; David Goldenberg; Sachin Mehta; Edward Quinlan; Mark Barakat

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4620. doi:

ARVO Annual Meeting Abstract June 2017

No Clear Benefit of Vitrectomy for Post-Injection Endophthalmitis in Age-Related Macular Degeneration

Mark Barakat; Neal Palejwala; Ashleigh L Levison; Sujit Itty; Milad Haak; Sachin Mehta; David Goldenberg; karim jamal; Edward Quinlan; Derek Kunimoto; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5499. doi:

ARVO Annual Meeting Abstract September 2016

Clinical outcomes of treatment switching in neovascular age-related macular degeneration (nAMD): a retrospective cohort study in the United States (US) using electronic medical records

Frances Milnes; Raymond Griner; Alberto Ferreira; Adrian Skelly; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3365. doi:

ARVO Annual Meeting Abstract September 2016

Consistency of visual acuity response to anti-VEGF therapy in diabetic macular edema patients: An analysis of DRCRnet Protocol I data

Scott M Whitcup; Joanna Campbell; Nancy Holekamp; Szilard Kiss; Anat Loewenstein; Albert J Augustin; Allen C Ho; Victor Gonzalez; Vanessa Shih; Amelia Orejudos; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Real-World Assessment of Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Interim Analysis from the REINFORCE Study

Howard F Fine; Michael Singer; Pravin U Dugel; Antonio Capone, Jr.; John Maltman

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3259. doi:

ARVO Annual Meeting Abstract September 2016

A first in human study of Intravitreal (IVT) CLG561 in Subjects with Advanced Age-Related Macular Degeneration (AMD)

Louis C Glazer; Jonathan G. Williams; Carmelina M Gordon; Pravin U Dugel; Mark Milton; Thomas Valencia; Ulf Klein; Sandrine Kretz; Kinfemichael Gedif; Cynthia L Grosskreutz; Parisa Zamiri

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2672. doi:

ARVO Annual Meeting Abstract September 2016

A 2-year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age-related macular degeneration: testing an alternative treatment regimen

Pravin U Dugel; James Warburton; Andreas Weichselberger; Peter Sallstig

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5018. doi:

ARVO Annual Meeting Abstract June 2015

Anti-VEGF resistance in neovascular AMD: Role of PDGF antagonism

Pravin U Dugel; Derek Kunimoto; Edward Quinlan; Karim Jamal; David Goldenberg; Sachin Mehta; Matthew Witmer; Mark Barakat; Milad Hakimbashi

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2826. doi:

ARVO Annual Meeting Abstract June 2015

Comorbidity and Healthcare Visit Burden in Elderly Diabetic Macular Edema Patients

Joanna Campbell; Pravin U Dugel; Ashley Cole; Orsolya Lunacsek; Amanda Forys; Herman Chen; Hitesh Chandwani; Szilard Kiss

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2145. doi:

ARVO Annual Meeting Abstract June 2015

Comorbidity and healthcare visit burden in working-age commercially insured diabetic macular edema patients

Hitesh Chandwani; Szilard Kiss; Ashley Cole; Vaishali D Patel; Orsolya Lunacsek; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2146. doi:

ARVO Annual Meeting Abstract April 2014

Treatment Patterns and Associated Costs of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration

Szilard Kiss; Pravin U Dugel; Kathleen Wilson; Alice Huang; David Smith; Helen Varker; Stephen S Johnston; Adam Turpcu

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5596. doi:

ARVO Annual Meeting Abstract April 2014

Safety and Efficacy of Two or More Dexamethasone Intravitreal Implants in Treatment-Naïve Patients with Macular Edema Due to Retinal Vein Occlusion

Michael Singer; Antonio Capone; Pravin U Dugel; Richard F Dreyer; David G Dodwell; Daniel B Roth; Rui Shi; John G Walt; Lanita C Scott; David A Hollander

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1797. doi:

ARVO Annual Meeting Abstract April 2014

Two or More Dexamethasone Intravitreal Implants Used as Monotherapy or Combined With Other Therapy in Retinal Vein Occlusion

David G Dodwell; Antonio Capone; Michael Singer; Pravin U Dugel; Richard F Dreyer; Daniel B Roth; Rui Shi; John G Walt; Lanita C Scott; David A Hollander

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1807. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Specify Date Range

Predictability of the 12-week dosing status at Week 48 for patients receiving brolucizumab in HAWK and HARRIER

Comparative assessment of anatomical outcomes for nAMD patients treated with brolucizumab and aflibercept: 16-week data from the HAWK and HARRIER studies

Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER

Quantitative assessment of changes in retinal vascular density and morphology among patients with diabetic retinopathy using spectral domain optical coherence tomography angiography (SD-OCTA)

Quantitative spectral-domain optical coherence tomography angiography (OCTA) of Diabetic Retinopathy (DR) Severity

Persistent diabetic macular edema after 6 months of anti-VEGF therapy is associated with diminished long-term improvement in vision: a post-hoc analysis of Protocol I

3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration

Assessing the safety and efficacy of dexamethasone intraocular implant for macular edema after cataract surgery in patients with diabetes.

No Clear Benefit of Vitrectomy for Post-Injection Endophthalmitis in Age-Related Macular Degeneration

Clinical outcomes of treatment switching in neovascular age-related macular degeneration (nAMD): a retrospective cohort study in the United States (US) using electronic medical records

Consistency of visual acuity response to anti-VEGF therapy in diabetic macular edema patients: An analysis of DRCRnet Protocol I data

Real-World Assessment of Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Interim Analysis from the REINFORCE Study

A first in human study of Intravitreal (IVT) CLG561 in Subjects with Advanced Age-Related Macular Degeneration (AMD)

A 2-year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age-related macular degeneration: testing an alternative treatment regimen

Anti-VEGF resistance in neovascular AMD: Role of PDGF antagonism

Comorbidity and Healthcare Visit Burden in Elderly Diabetic Macular Edema Patients

Comorbidity and healthcare visit burden in working-age commercially insured diabetic macular edema patients

Treatment Patterns and Associated Costs of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration

Safety and Efficacy of Two or More Dexamethasone Intravitreal Implants in Treatment-Naïve Patients with Macular Edema Due to Retinal Vein Occlusion

Two or More Dexamethasone Intravitreal Implants Used as Monotherapy or Combined With Other Therapy in Retinal Vein Occlusion

To View More...

You must be signed into an individual account to use this feature.